Real world outcomes of intra-vitreal Injection of ocriplasmin for vitreo-macular traction

Poster Details

First Author: S.Ramanathan UK

Co Author(s):                                 

Abstract Details


To evaluate the safety and efficacy of intra-vitreal Injection of Ocriplasmin for Vitreo-macular traction.


The Royle Eye Unit, Pilgrim Hospital, Boston, UK PE21 9QS


Twenty one eyes of 21 patients, who presented with Vitreo-macular traction (VMT) were included in the study. Age: Mean 78.86 (Range 70-94), M:F= 8:13. Comorbidity included advanced glaucoma, Dry Macular Degeneration, Diabetic Maculopathy, Neovascular AMD, ERM, CRVO and Ocular Hypertention. In order to eliminate the possibility of spontaneous resolution, a minimum period of 3 months was allowed between diagnosis of VMT and intravitreal injection of Ocriplasmin. All patients were monitored within 2 weeks of injection and thereafter at 4-6 week intervals. At each visit, adverse events, visual symptoms, Visual acuity and optical coherence tomography morphology were evaluated. Earliest treatment was performed in March 2015 and the latest treatment in December 2016.


• 6/21 (29%) eyes had full resolution of VMT, 2 patients had resolution of traction with persistent vitreo-macular adhesion with improvement of vision. • Overall 8/21 (38%) patients had benefitted from the treatment. • Post injection adverse symptoms/events were of 2-5 days duration and included pain, photopsia, floaters and blurred vision.


The results compare well with previous studies and our data show that intrvitreal injection of Ocriplasmin is a worthwhile intervention for vitreo-macular traction.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email:

Privacy policyHotel Terms and Conditions Cancellation policy